Frederick et al., "Performance of the thrombolysis in myocardial infarction
risk index in the national registry of myocardial infarction-3 and-4: a simple index that predicts mortality in ST-segment elevation myocardial infarction," Journal of the American College of Cardiology, vol.
ACS: acute coronary syndrome; AMI: acute myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; MI: myocardial infarction; MPV: mean platelet volume; STEMI: ST elevation myocardial infarction; CAD: coronary artery disease; TIMI: thrombolysis in myocardial infarction
; WBC: white blood cell count; RDW: red blood cell distribution width; PDW: platelet distribution width; PLR: platelet lymphocyte ratio; P-LCR: platelet large cell ratio; CVD: cardiovascular disease; HF: heart failure; PCI: percutaneous coronary intervention; RVD: right ventricular dysfunction; MACEs: major adverse cardiac events; GRACE: global registry of acute coronary events; SCF: slow coronary flow; IMT: intima media thickness.
Also, criteria for reperfusion in all patients after thrombolysis, number of patients with thrombolysis in myocardial infarction
(TIMI) grade 3 coronary reperfusion and coronary artery lesions were recorded.
The patients had grade 0 or 1 thrombolysis in myocardial infarction
(TIMI) during initial coronary angioplasty within 12 h of the onset of symptoms.
LM: left main coronary artery; LAD: left anterior descending coronary artery; LCA: left circumflex artery; RCA: right coronary artery; TIMI: thrombolysis in myocardial infarction
; PCI: percutaneous coronary intervention; IABP: intra-aortic balloon pump; GPI: glycoprotein IIb/IIIa inhibitors; LVEF: left ventricular ejection fraction.
The Thrombolysis in Myocardial Infarction
(TIMI) Trial: phase I findings.
The trial's primary endpoint was a composite of all bleeding events according to the TIMI (thrombolysis in myocardial infarction
) classification and it was evaluated for all patients within 30 days of study drug administration.
He analyzed the records of 20,101 acute MI patients who participated in the Thrombolysis in Myocardial Infarction
(TIMI) 4, 9A, 9B, and 10B trials and in the Intravenous NPA [lanoteplase] for Treatment of Infarcting Myocardium Early-II (In TIME-II) trial.
The Phase II trial will be conducted by the US-based Thrombolysis in Myocardial Infarction
(TIMI) Study Group in suitable heart attack patients, initially at two hospitals in the United States.
No differences in outcomes between groups were observed in prespecified subgroup analyses according to age, diabetic status, infarction location, Thrombolysis In Myocardial Infarction
(TIMI) flow, and time elapsed from first medical contact to balloon time
According to Thrombolysis in myocardial infarction
(TIMI), the patients were divided into a reflow group and a no-reflow group.
Thrombolysis in myocardial infarction
: impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy.